Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT tr...
Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
The rate of decline in forced expiratory volume in 1 second (FEV1) is representative of the natural history of COPD. Sparse information exists regarding the associations between the magnitude of annualised loss of FEV1 with other endpoints.
Retrospective analysis of UPLIFT® trial (four-year, randomized, double-blind, placebo-controlled trial of...
Alternative Titles
Full title
Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_adb03b64a4c3483e98a24d9fc5d58479
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_adb03b64a4c3483e98a24d9fc5d58479
Other Identifiers
ISSN
1465-993X,1465-9921
E-ISSN
1465-993X,1465-9921
DOI
10.1186/1465-9921-12-129
